Myocardial infarction, the number one cause of sudden death in adults and the number two cause of death in Korea, is a deadly disease with an initial mortality rate of 30%, and about 5%–10% of ...

The elderly account for the majority of medical spending in many countries, raising concerns about potentially unnecessary spending, especially during the final months of life. Using a well-defined ...

Myocardial infarction, or a heart attack, remains the most common cause of heart failure (HF) worldwide. Although there are treatments that aid in overall heart health, there are few preventative ...

IRVINE, Calif.--(BUSINESS WIRE)--TherOx, Inc., a privately held medical device company focused on improving treatment of acute myocardial infarction (AMI), announced that the U.S. Food and Drug ...

Myocardial infarction is an ischemic disease in which a coronary artery supplying blood to the heart muscle is stenotic or obstructed, resulting in cardiac tissue necrosis. Due to the irreversible ...

The benefit of complete revascularization in older patients (≥75 years of age) with myocardial infarction and multivessel disease remains unclear. In this multicenter, randomized trial, we assigned ...

Prehospital pulse-dose glucocorticoid treatment in patients with ST-segment elevation myocardial infarction (STEMI) does not reduce the final infarct size at 3 months but may improve acute outcomes ...

The world's first clinical trial to test glenzocimab as a potential new drug to improve the long-term outcomes for heart attack patients will take place in the UK. Glenzocimab is a humanised ...

(HealthDay)—Use of sex-specific diagnostic thresholds for myocardial infarction identifies more additional women than men with myocardial injury, but women are less likely to receive treatment, ...